Trial Outcomes & Findings for Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation) (NCT NCT02839889)
NCT ID: NCT02839889
Last Updated: 2019-03-05
Results Overview
Change from baseline in mean daily NRS (Numerical Rating Scale) values will be calculated as the post-baseline value minus the baseline. Baseline NRS is the mean daily NRS values recorded during the Opioid Induced Constipation (OIC) Confirmation period. Numeric Rating Scale is 0-10. 0 is no pain and 10 is worst possible pain. Lower values are a better outcome and higher values are a worse outcome. Post-baseline values were calculated as the mean of NRS scores during visits 2-4.
TERMINATED
PHASE4
12 participants
Assessed from screening/Opioid Induced Constipation (OIC) Confirmation period through study completion, approximately 6 weeks.
2019-03-05
Participant Flow
This multi center was conducted at 3 sites in the US. Enrollment to the study was stopped due to recruitment challenges and no new patients have been screened as of January 2018. 5 patients were randomized across the 2 treatment groups.
To confirm eligibility participants underwent a 7 day baseline assessment/OIC confirmation period. 12 patients provided consent for this study, however 7 did not fulfill eligibility criteria during the 7 day baseline period.
Participant milestones
| Measure |
Placebo
Placebo once daily for two weeks
Placebo: Placebo once daily for two weeks, followed by two week open-label period
|
Naloxegol
Naloxegol 25mg tablets once daily for two weeks
Naloxegol: Naloxegol 25mg tablets for two weeks, followed by a two week open-label period
|
|---|---|---|
|
Randomization Period
STARTED
|
2
|
3
|
|
Randomization Period
COMPLETED
|
2
|
3
|
|
Randomization Period
NOT COMPLETED
|
0
|
0
|
|
Open-Label Period
STARTED
|
0
|
5
|
|
Open-Label Period
COMPLETED
|
0
|
4
|
|
Open-Label Period
NOT COMPLETED
|
0
|
1
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation)
Baseline characteristics by cohort
| Measure |
Placebo
n=2 Participants
Placebo once daily for two weeks
Placebo: Placebo once daily for two weeks, followed by two week open-label period
|
Naloxegol
n=3 Participants
Naloxegol 25mg tablets once daily for two weeks
Naloxegol: Naloxegol 25mg tablets for two weeks, followed by a two week open-label period
|
Total
n=5 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
1 Participants
n=99 Participants
|
1 Participants
n=107 Participants
|
2 Participants
n=206 Participants
|
|
Age, Categorical
>=65 years
|
1 Participants
n=99 Participants
|
2 Participants
n=107 Participants
|
3 Participants
n=206 Participants
|
|
Sex: Female, Male
Female
|
1 Participants
n=99 Participants
|
1 Participants
n=107 Participants
|
2 Participants
n=206 Participants
|
|
Sex: Female, Male
Male
|
1 Participants
n=99 Participants
|
2 Participants
n=107 Participants
|
3 Participants
n=206 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Black or African American
|
1 Participants
n=99 Participants
|
1 Participants
n=107 Participants
|
2 Participants
n=206 Participants
|
|
Race (NIH/OMB)
White
|
1 Participants
n=99 Participants
|
2 Participants
n=107 Participants
|
3 Participants
n=206 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Region of Enrollment
United States
|
2 participants
n=99 Participants
|
3 participants
n=107 Participants
|
5 participants
n=206 Participants
|
|
Baseline Numerical Rating Scale (NRS) for Pain
|
5.7 score on a scale
n=99 Participants
|
6.2 score on a scale
n=107 Participants
|
6.0 score on a scale
n=206 Participants
|
|
Baseline Electrocardiogram QTC Interval
|
430.8 Milliseconds
n=99 Participants
|
414.5 Milliseconds
n=107 Participants
|
421 Milliseconds
n=206 Participants
|
|
Baseline Electrocardiogram Heart Rate
|
82 beats per minute
n=99 Participants
|
79 beats per minute
n=107 Participants
|
80.2 beats per minute
n=206 Participants
|
|
Baseline Daily Opioid Use
|
300 morphine milligram equivalents per day
n=99 Participants
|
126.5 morphine milligram equivalents per day
n=107 Participants
|
196 morphine milligram equivalents per day
n=206 Participants
|
|
Baseline Systolic Blood Pressure
|
133.5 mmHg
n=99 Participants
|
118 mmHg
n=107 Participants
|
124.2 mmHg
n=206 Participants
|
|
Baseline Diastolic Blood Pressure
|
85 mmHg
n=99 Participants
|
71.3 mmHg
n=107 Participants
|
76.8 mmHg
n=206 Participants
|
|
Baseline Pulse Rate
|
81 beats per minute
n=99 Participants
|
79 beats per minute
n=107 Participants
|
79.8 beats per minute
n=206 Participants
|
|
Baseline Bristol Stool Scale score
|
3.91 score on a scale
n=99 Participants
|
1.94 score on a scale
n=107 Participants
|
2.73 score on a scale
n=206 Participants
|
|
Baseline Respiratory Rate
|
14 breaths per minute
n=99 Participants
|
15.3 breaths per minute
n=107 Participants
|
14.8 breaths per minute
n=206 Participants
|
|
Baseline Degree of Straining
|
2.21 score on a scale
n=99 Participants
|
2.06 score on a scale
n=107 Participants
|
2.12 score on a scale
n=206 Participants
|
|
Baseline Complete Evacuation with Bowel Movements
|
39.3 % of days with complete evacuation
n=99 Participants
|
41.7 % of days with complete evacuation
n=107 Participants
|
40.7 % of days with complete evacuation
n=206 Participants
|
|
Baseline Patient Assessment of Constipation Symptom Assessments (PAC-SYM)
Abdominal symptoms
|
6.5 score on a scale
n=99 Participants
|
8 score on a scale
n=107 Participants
|
7.4 score on a scale
n=206 Participants
|
|
Baseline Patient Assessment of Constipation Symptom Assessments (PAC-SYM)
Rectal Symptoms
|
2 score on a scale
n=99 Participants
|
3.3 score on a scale
n=107 Participants
|
2.8 score on a scale
n=206 Participants
|
|
Baseline Patient Assessment of Constipation Symptom Assessments (PAC-SYM)
Stool symptoms
|
7.5 score on a scale
n=99 Participants
|
8 score on a scale
n=107 Participants
|
7.8 score on a scale
n=206 Participants
|
|
Baseline Patient Assessment of Constipation Symptom Assessments (PAC-SYM)
Total Score
|
16 score on a scale
n=99 Participants
|
19.3 score on a scale
n=107 Participants
|
18 score on a scale
n=206 Participants
|
|
Baseline Patient Assessment of Constipation (PAC-QOL)
Physical Discomfort
|
8 score on a scale
n=99 Participants
|
4.7 score on a scale
n=107 Participants
|
6 score on a scale
n=206 Participants
|
|
Baseline Patient Assessment of Constipation (PAC-QOL)
Psychosocial discomfort
|
14 score on a scale
n=99 Participants
|
4.3 score on a scale
n=107 Participants
|
8.2 score on a scale
n=206 Participants
|
|
Baseline Patient Assessment of Constipation (PAC-QOL)
Worries/concerns
|
17 score on a scale
n=99 Participants
|
15.3 score on a scale
n=107 Participants
|
16 score on a scale
n=206 Participants
|
|
Baseline Patient Assessment of Constipation (PAC-QOL)
Satisfaction
|
5.5 score on a scale
n=99 Participants
|
3.3 score on a scale
n=107 Participants
|
4.2 score on a scale
n=206 Participants
|
|
Baseline Patient Assessment of Constipation (PAC-QOL)
Total Score
|
44.5 score on a scale
n=99 Participants
|
27.7 score on a scale
n=107 Participants
|
34.4 score on a scale
n=206 Participants
|
PRIMARY outcome
Timeframe: Assessed from screening/Opioid Induced Constipation (OIC) Confirmation period through study completion, approximately 6 weeks.Change from baseline in mean daily NRS (Numerical Rating Scale) values will be calculated as the post-baseline value minus the baseline. Baseline NRS is the mean daily NRS values recorded during the Opioid Induced Constipation (OIC) Confirmation period. Numeric Rating Scale is 0-10. 0 is no pain and 10 is worst possible pain. Lower values are a better outcome and higher values are a worse outcome. Post-baseline values were calculated as the mean of NRS scores during visits 2-4.
Outcome measures
| Measure |
Placebo
n=2 Participants
Placebo once daily for two weeks
Placebo: Placebo once daily for two weeks, followed by two week open-label period
|
Naloxegol
n=3 Participants
Naloxegol 25mg tablets once daily for two weeks
Naloxegol: Naloxegol 25mg tablets for two weeks, followed by a two week open-label period
|
|---|---|---|
|
Numerical Rating Scale (NRS) for Pain Change From Baseline
|
0.65 score on a scale
Interval 0.3 to 1.0
|
.33 score on a scale
Interval -0.4 to 1.4
|
PRIMARY outcome
Timeframe: Assessed from screening through study completion, approximately 6 weeks.Change from baseline in mean daily opioid dose will be calculated as the post-baseline value minus the baseline value. Positive changes from baseline indicate there was a need to increase the opioid dose. Baseline daily opioid dose is the mean daily opioid dose recorded during the Opioid Induced Constipation (OIC) Confirmation period.
Outcome measures
| Measure |
Placebo
n=2 Participants
Placebo once daily for two weeks
Placebo: Placebo once daily for two weeks, followed by two week open-label period
|
Naloxegol
n=3 Participants
Naloxegol 25mg tablets once daily for two weeks
Naloxegol: Naloxegol 25mg tablets for two weeks, followed by a two week open-label period
|
|---|---|---|
|
Daily Opioid Use Change From Baseline
|
1144 morphine milligram equivalents per day
Interval 0.0 to 2288.0
|
20 morphine milligram equivalents per day
Interval 0.0 to 60.0
|
PRIMARY outcome
Timeframe: Change from Baseline at End of Double Blind Phase (Visit 3, approximately day 15)Population: All abnormal lab values were deemed not clinically significant by Investigators. Therefore, changes did not meet the criteria for an adverse event and changes were not collected.
Changes from Baseline to Visit 3 (approximately Day 15) for all patients will be calculated as the post-baseline test value minus the baseline test value.
Outcome measures
Outcome data not reported
PRIMARY outcome
Timeframe: Change from Baseline at End of Double Blind Phase (Visit 3, approximately day 15)Changes from Baseline to Visit 3 (approximately Day 15) for Electrocardiogram (ECG) QTC interval data will be derived by subtracting the baseline value from the final assessment data.
Outcome measures
| Measure |
Placebo
n=2 Participants
Placebo once daily for two weeks
Placebo: Placebo once daily for two weeks, followed by two week open-label period
|
Naloxegol
n=3 Participants
Naloxegol 25mg tablets once daily for two weeks
Naloxegol: Naloxegol 25mg tablets for two weeks, followed by a two week open-label period
|
|---|---|---|
|
Electrocardiogram QTC Interval
|
-24.8 milliseconds
Interval -61.6 to 12.0
|
-6.9 milliseconds
Interval -17.0 to 4.0
|
PRIMARY outcome
Timeframe: Change from Baseline at End of Double Blind Phase (Visit 3, approximately day 15)Changes from Baseline to Visit 3 (approximately Day 15) for Electrocardiogram (ECG) heart rate data will be derived by subtracting the baseline value from the final assessment data.
Outcome measures
| Measure |
Placebo
n=2 Participants
Placebo once daily for two weeks
Placebo: Placebo once daily for two weeks, followed by two week open-label period
|
Naloxegol
n=3 Participants
Naloxegol 25mg tablets once daily for two weeks
Naloxegol: Naloxegol 25mg tablets for two weeks, followed by a two week open-label period
|
|---|---|---|
|
Electrocardiogram Heart Rate
|
9 beats per minute
Interval 7.0 to 11.0
|
10 beats per minute
Interval 2.0 to 23.0
|
PRIMARY outcome
Timeframe: Change from Baseline in systolic blood pressure through study completion, approximately 6 weeks.Change from Baseline in systolic blood pressure at post baseline (visits 2, 3, 4) will be derived as the value at the visit minus the baseline value for the same assessment. The post-baseline values were calculated as a mean of values from visits 2 through 4.
Outcome measures
| Measure |
Placebo
n=2 Participants
Placebo once daily for two weeks
Placebo: Placebo once daily for two weeks, followed by two week open-label period
|
Naloxegol
n=3 Participants
Naloxegol 25mg tablets once daily for two weeks
Naloxegol: Naloxegol 25mg tablets for two weeks, followed by a two week open-label period
|
|---|---|---|
|
Change From Baseline in Systolic Blood Pressure
|
-10.3 mmHg
Interval -30.3 to 9.7
|
-8.8 mmHg
Interval -19.0 to 7.3
|
PRIMARY outcome
Timeframe: Change from Baseline in diastolic blood pressure through study completion, approximately 6 weeks.Change from Baseline in diastolic blood pressure at post baseline (visits 2, 3, 4) will be derived as the value at the visit minus the baseline value for the same assessment. The post-baseline values were calculated as a mean of values from visits 2 through 4.
Outcome measures
| Measure |
Placebo
n=2 Participants
Placebo once daily for two weeks
Placebo: Placebo once daily for two weeks, followed by two week open-label period
|
Naloxegol
n=3 Participants
Naloxegol 25mg tablets once daily for two weeks
Naloxegol: Naloxegol 25mg tablets for two weeks, followed by a two week open-label period
|
|---|---|---|
|
Change From Baseline in Diastolic Blood Pressure
|
-10.5 mmHg
Interval -20.0 to -1.0
|
-1.8 mmHg
Interval -9.3 to 4.0
|
PRIMARY outcome
Timeframe: Change from Baseline in respiratory rate through study completion, approximately 6 weeks.Change from Baseline in respiratory rate at post baseline (visits 2, 3, 4) will be derived as the value at the visit minus the baseline value for the same assessment. The post-baseline values were calculated as a mean of values from visits 2 through 4.
Outcome measures
| Measure |
Placebo
n=2 Participants
Placebo once daily for two weeks
Placebo: Placebo once daily for two weeks, followed by two week open-label period
|
Naloxegol
n=3 Participants
Naloxegol 25mg tablets once daily for two weeks
Naloxegol: Naloxegol 25mg tablets for two weeks, followed by a two week open-label period
|
|---|---|---|
|
Change From Baseline in Respiratory Rate
|
1.7 breaths per minute
Interval -2.0 to 5.3
|
1.2 breaths per minute
Interval -0.7 to 3.7
|
PRIMARY outcome
Timeframe: Change from Baseline in pulse rate through study completion, approximately 6 weeks.Change from Baseline in pulse rate at post baseline (visits 2, 3, 4) will be derived as the value at the visit minus the baseline value for the same assessment. The post-baseline values were calculated as a mean of values from visits 2 through 4.
Outcome measures
| Measure |
Placebo
n=2 Participants
Placebo once daily for two weeks
Placebo: Placebo once daily for two weeks, followed by two week open-label period
|
Naloxegol
n=3 Participants
Naloxegol 25mg tablets once daily for two weeks
Naloxegol: Naloxegol 25mg tablets for two weeks, followed by a two week open-label period
|
|---|---|---|
|
Change From Baseline in Pulse Rate
|
4.5 beats per minute
Interval 3.7 to 5.3
|
10.3 beats per minute
Interval 5.3 to 15.3
|
SECONDARY outcome
Timeframe: Assessed from Baseline through Study Completion, approximately 6 weeks.Daily diary data will be used to identify RFBMs. The weekly RFBM frequency within each time period will be calculated as: (Total number of RFBMs during the time period of interest/number of days) x 7. RFBM rate calculated from post baseline period.
Outcome measures
| Measure |
Placebo
n=2 Participants
Placebo once daily for two weeks
Placebo: Placebo once daily for two weeks, followed by two week open-label period
|
Naloxegol
n=3 Participants
Naloxegol 25mg tablets once daily for two weeks
Naloxegol: Naloxegol 25mg tablets for two weeks, followed by a two week open-label period
|
|---|---|---|
|
Rescue Free Bowel Movements (RFBM) Responder Rate
|
8.14 RFBMs/days *7
Interval 3.5 to 12.79
|
3.82 RFBMs/days *7
Interval 1.59 to 5.55
|
SECONDARY outcome
Timeframe: First dose date to first post-dose rescue free bowel movementTime (in hours) to first post-dose rescue free bowel movement minus first dose date and time.
Outcome measures
| Measure |
Placebo
n=2 Participants
Placebo once daily for two weeks
Placebo: Placebo once daily for two weeks, followed by two week open-label period
|
Naloxegol
n=3 Participants
Naloxegol 25mg tablets once daily for two weeks
Naloxegol: Naloxegol 25mg tablets for two weeks, followed by a two week open-label period
|
|---|---|---|
|
Time to First Post-dose Rescue Free Laxation
|
23.3 Hours
Interval 17.96 to 28.58
|
33.5 Hours
Interval 3.67 to 67.73
|
SECONDARY outcome
Timeframe: Assessed from baseline through Study Completion, approximately 6 weeks.The Bristol Stool Scale classifies the type of bowel movement on a scale from 1-7, based on the appearance of stool. 1 indicates severe constipation, 2 indicates mild constipation, 3-4 indicate a normal bowel movement, 5 indicates that the patient is lacking dietary fiber, 6 indicates mild diarrhea, and 7 indicates severe diarrhea. A better score would trend toward the middle of the scale (ranges 3-4), while scores at either end of the scale correspond to worse outcomes. Bristol Stool Scale (BSS) Score calculated by the sum of daily BSS scores divided by the number of bowel movements that occurred from baseline to study completion. Change from Baseline calculated as the Baseline value minus the post-baseline value.
Outcome measures
| Measure |
Placebo
n=2 Participants
Placebo once daily for two weeks
Placebo: Placebo once daily for two weeks, followed by two week open-label period
|
Naloxegol
n=3 Participants
Naloxegol 25mg tablets once daily for two weeks
Naloxegol: Naloxegol 25mg tablets for two weeks, followed by a two week open-label period
|
|---|---|---|
|
Bristol Stool Scale (BSS) Score
|
-.06 score on a scale
Interval -0.4 to 0.28
|
2.37 score on a scale
Interval 1.51 to 3.02
|
SECONDARY outcome
Timeframe: day 1, day 15, day 29The PAC-SYM is divided into three subscales. Each item is scored 0-4. Items 1-4 measure abdominal symptoms (total subscale range 0-16), items 5-7 measure rectal symptoms (total subscale score 0-12), and items 8-12 measure stool symptoms (total subscale range 0-20). For each subscale, lower scores are better and higher scores are worse. The total construct score is generated by summing the scores of the subscales. This total score ranges from 0-48, with lower scores corresponding to better outcomes, and higher scores corresponding to worse outcomes. Change from baseline in mean values calculated as post-baseline value minus baseline value for each scale, and for total. Post-baseline values defined as the mean of day 15 and day 29.
Outcome measures
| Measure |
Placebo
n=2 Participants
Placebo once daily for two weeks
Placebo: Placebo once daily for two weeks, followed by two week open-label period
|
Naloxegol
n=3 Participants
Naloxegol 25mg tablets once daily for two weeks
Naloxegol: Naloxegol 25mg tablets for two weeks, followed by a two week open-label period
|
|---|---|---|
|
Patient Assessment of Constipation Symptoms (PAC-SYM)
Abdominal Symptoms
|
1 score on a scale
Interval 0.0 to 2.0
|
.5 score on a scale
Interval -2.0 to 3.0
|
|
Patient Assessment of Constipation Symptoms (PAC-SYM)
Rectal Symptoms
|
1.25 score on a scale
Interval 1.0 to 1.5
|
1.2 score on a scale
Interval -1.5 to 5.0
|
|
Patient Assessment of Constipation Symptoms (PAC-SYM)
Stool Symptoms
|
.5 score on a scale
Interval -0.5 to 1.5
|
-.2 score on a scale
Interval -1.5 to 1.5
|
|
Patient Assessment of Constipation Symptoms (PAC-SYM)
Total Score
|
2.75 score on a scale
Interval 2.5 to 3.0
|
1.5 score on a scale
Interval -3.5 to 9.5
|
SECONDARY outcome
Timeframe: day 1, day 15, day 29The PAC-QOL is a 28-item questionnaire divided into 4 subscales. Items 1-4 measure physical discomfort (subscale range 0-16), 5-12 measure psychosocial discomfort (range 0-32), 13-23 measure worries/concerns (range 0-44), and 24-28 measure satisfaction (range 0-20). For each subscale, lower scores are better and higher scores are worse. The total score is generated by summing the scores of the subscales. This total score ranges from 0-112, with lower scores corresponding to better outcomes, and higher scores corresponding to worse outcomes. Change from baseline in mean values calculated as post-baseline value minus baseline value for each subscale, and for total. Post-baseline values defined as the mean of day 15 and day 29.
Outcome measures
| Measure |
Placebo
n=2 Participants
Placebo once daily for two weeks
Placebo: Placebo once daily for two weeks, followed by two week open-label period
|
Naloxegol
n=3 Participants
Naloxegol 25mg tablets once daily for two weeks
Naloxegol: Naloxegol 25mg tablets for two weeks, followed by a two week open-label period
|
|---|---|---|
|
Patient Assessment of Constipation Quality of Life (PAC-QOL)
Physical discomfort
|
-1.25 score on a scale
Interval -1.5 to -1.0
|
0.17 score on a scale
Interval 0.0 to 0.5
|
|
Patient Assessment of Constipation Quality of Life (PAC-QOL)
Psychosocial Discomfort
|
-1 score on a scale
Interval -9.0 to 7.0
|
6 score on a scale
Interval 1.0 to 14.0
|
|
Patient Assessment of Constipation Quality of Life (PAC-QOL)
Worries/concerns
|
1.5 score on a scale
Interval -3.5 to 6.5
|
1.17 score on a scale
Interval -1.5 to 3.5
|
|
Patient Assessment of Constipation Quality of Life (PAC-QOL)
Satisfaction
|
3.5 score on a scale
Interval 2.0 to 5.0
|
3.83 score on a scale
Interval 2.0 to 6.5
|
|
Patient Assessment of Constipation Quality of Life (PAC-QOL)
Total Score
|
2.75 score on a scale
Interval -12.0 to 17.5
|
11.17 score on a scale
Interval 5.5 to 20.0
|
SECONDARY outcome
Timeframe: Assessed at baseline through Study Completion with each bowel movement, approximately 6 weeks.Degree of straining scale is 1 to 5 with 1 being "not at all" and 5 being "an extreme amount". Lower scores are better and higher scores are worse. Change from baseline in mean values calculated as the post baseline value minus the baseline. Degree of Straining scale change from baseline mean scores calculated from baseline to study completion.
Outcome measures
| Measure |
Placebo
n=2 Participants
Placebo once daily for two weeks
Placebo: Placebo once daily for two weeks, followed by two week open-label period
|
Naloxegol
n=3 Participants
Naloxegol 25mg tablets once daily for two weeks
Naloxegol: Naloxegol 25mg tablets for two weeks, followed by a two week open-label period
|
|---|---|---|
|
Degree of Straining Question With Each Bowel Movement
|
.6 score on a scale
Interval -0.31 to 1.5
|
-.35 score on a scale
Interval -0.67 to 0.09
|
SECONDARY outcome
Timeframe: Assessed at baseline through Study Completion with each bowel movement, approximately 6 weeks.Change from Baseline in mean values calculated as the post baseline value minus the baseline. The post baseline value is the percentage of days from baseline to study completion with at least one complete bowel evacuation.
Outcome measures
| Measure |
Placebo
n=2 Participants
Placebo once daily for two weeks
Placebo: Placebo once daily for two weeks, followed by two week open-label period
|
Naloxegol
n=3 Participants
Naloxegol 25mg tablets once daily for two weeks
Naloxegol: Naloxegol 25mg tablets for two weeks, followed by a two week open-label period
|
|---|---|---|
|
Complete Evacuation Question With Each Bowel Movement
|
21.92 % of days with complete evacuation
Interval 21.43 to 22.41
|
7.7 % of days with complete evacuation
Interval -11.36 to 79.31
|
Adverse Events
Placebo
Naloxegol
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
Placebo
n=2 participants at risk
Placebo once daily for two weeks
Placebo: Placebo once daily for two weeks, followed by two week open-label period
|
Naloxegol
n=3 participants at risk
Naloxegol 25mg tablets once daily for two weeks
Naloxegol: Naloxegol 25mg tablets for two weeks, followed by a two week open-label period
|
|---|---|---|
|
Gastrointestinal disorders
Nausea
|
50.0%
1/2 • Number of events 2 • Occurrences from Baseline through study completion, approximately 6 weeks
|
0.00%
0/3 • Occurrences from Baseline through study completion, approximately 6 weeks
|
|
Gastrointestinal disorders
Gastroesophageal reflux disease
|
50.0%
1/2 • Number of events 1 • Occurrences from Baseline through study completion, approximately 6 weeks
|
0.00%
0/3 • Occurrences from Baseline through study completion, approximately 6 weeks
|
|
General disorders
fever
|
50.0%
1/2 • Number of events 1 • Occurrences from Baseline through study completion, approximately 6 weeks
|
0.00%
0/3 • Occurrences from Baseline through study completion, approximately 6 weeks
|
|
General disorders
chills
|
50.0%
1/2 • Number of events 1 • Occurrences from Baseline through study completion, approximately 6 weeks
|
0.00%
0/3 • Occurrences from Baseline through study completion, approximately 6 weeks
|
|
Gastrointestinal disorders
diarrhea
|
100.0%
2/2 • Number of events 2 • Occurrences from Baseline through study completion, approximately 6 weeks
|
0.00%
0/3 • Occurrences from Baseline through study completion, approximately 6 weeks
|
|
General disorders
abdominal distention
|
50.0%
1/2 • Number of events 1 • Occurrences from Baseline through study completion, approximately 6 weeks
|
0.00%
0/3 • Occurrences from Baseline through study completion, approximately 6 weeks
|
|
Renal and urinary disorders
bladder spasms
|
0.00%
0/2 • Occurrences from Baseline through study completion, approximately 6 weeks
|
33.3%
1/3 • Number of events 1 • Occurrences from Baseline through study completion, approximately 6 weeks
|
|
Musculoskeletal and connective tissue disorders
increased back pain
|
0.00%
0/2 • Occurrences from Baseline through study completion, approximately 6 weeks
|
33.3%
1/3 • Number of events 1 • Occurrences from Baseline through study completion, approximately 6 weeks
|
|
General disorders
increased abdominal pain
|
0.00%
0/2 • Occurrences from Baseline through study completion, approximately 6 weeks
|
33.3%
1/3 • Number of events 1 • Occurrences from Baseline through study completion, approximately 6 weeks
|
|
Gastrointestinal disorders
worsening constipation
|
0.00%
0/2 • Occurrences from Baseline through study completion, approximately 6 weeks
|
33.3%
1/3 • Number of events 1 • Occurrences from Baseline through study completion, approximately 6 weeks
|
|
Nervous system disorders
mental status changes
|
0.00%
0/2 • Occurrences from Baseline through study completion, approximately 6 weeks
|
33.3%
1/3 • Number of events 1 • Occurrences from Baseline through study completion, approximately 6 weeks
|
|
Gastrointestinal disorders
abdominal cramping
|
0.00%
0/2 • Occurrences from Baseline through study completion, approximately 6 weeks
|
33.3%
1/3 • Number of events 1 • Occurrences from Baseline through study completion, approximately 6 weeks
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place
Restriction type: LTE60